ABIOMED INC (ABMD) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ABMD • US0036541003

381.02 USD
+0.23 (+0.06%)
At close: Dec 21, 2022
381.3 USD
+0.28 (+0.07%)
After Hours: 12/21/2022, 8:15:55 PM
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to ABMD. ABMD was compared to 186 industry peers in the Health Care Equipment & Supplies industry. ABMD has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. ABMD is not valued too expensively and it also shows a decent growth rate. With these ratings, ABMD could be worth investigating further for quality investing!.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year ABMD was profitable.
  • ABMD had a positive operating cash flow in the past year.
ABMD Yearly Net Income VS EBIT VS OCF VS FCFABMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M

1.2 Ratios

  • ABMD's Return On Assets of 15.72% is amongst the best of the industry. ABMD outperforms 94.52% of its industry peers.
  • The Return On Equity of ABMD (17.32%) is better than 93.61% of its industry peers.
  • The Return On Invested Capital of ABMD (12.19%) is better than 89.95% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for ABMD is significantly above the industry average of 8.80%.
  • The last Return On Invested Capital (12.19%) for ABMD is well below the 3 year average (29.16%), which needs to be investigated, but indicates that ABMD had better years and this may not be a problem.
Industry RankSector Rank
ROA 15.72%
ROE 17.32%
ROIC 12.19%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)29.16%
ROIC(5y)N/A
ABMD Yearly ROA, ROE, ROICABMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 5 10 15 20 25

1.3 Margins

  • ABMD's Profit Margin of 24.84% is amongst the best of the industry. ABMD outperforms 95.43% of its industry peers.
  • In the last couple of years the Profit Margin of ABMD has grown nicely.
  • With an excellent Operating Margin value of 23.66%, ABMD belongs to the best of the industry, outperforming 93.61% of the companies in the same industry.
  • ABMD's Operating Margin has improved in the last couple of years.
Industry RankSector Rank
OM 23.66%
PM (TTM) 24.84%
GM N/A
OM growth 3Y-5.22%
OM growth 5Y4.22%
PM growth 3Y-26.75%
PM growth 5Y2.49%
GM growth 3YN/A
GM growth 5YN/A
ABMD Yearly Profit, Operating, Gross MarginsABMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 20 40 60 80

More info and screens

9

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so ABMD is creating value.
  • The number of shares outstanding for ABMD has been increased compared to 1 year ago.
  • There is no outstanding debt for ABMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ABMD Yearly Shares OutstandingABMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M
ABMD Yearly Total Debt VS Total AssetsABMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 500M 1B 1.5B

2.2 Solvency

  • ABMD has an Altman-Z score of 68.47. This indicates that ABMD is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 68.47, ABMD belongs to the top of the industry, outperforming 99.54% of the companies in the same industry.
  • ABMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 68.47
ROIC/WACC1.34
WACC9.07%
ABMD Yearly LT Debt VS Equity VS FCFABMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 7.93 indicates that ABMD has no problem at all paying its short term obligations.
  • The Current ratio of ABMD (7.93) is better than 83.11% of its industry peers.
  • ABMD has a Quick Ratio of 7.17. This indicates that ABMD is financially healthy and has no problem in meeting its short term obligations.
  • ABMD has a better Quick ratio (7.17) than 82.19% of its industry peers.
Industry RankSector Rank
Current Ratio 7.93
Quick Ratio 7.17
ABMD Yearly Current Assets VS Current LiabilitesABMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M 800M

More info and screens

6

3. Growth

3.1 Past

  • ABMD shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.78%.
  • Measured over the past years, ABMD shows a very strong growth in Earnings Per Share. The EPS has been growing by 30.92% on average per year.
  • Looking at the last year, ABMD shows a quite strong growth in Revenue. The Revenue has grown by 10.32% in the last year.
  • ABMD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.30% yearly.
EPS 1Y (TTM)-3.78%
EPS 3Y-2.48%
EPS 5Y30.92%
EPS Q2Q%26.21%
Revenue 1Y (TTM)10.32%
Revenue growth 3Y10.27%
Revenue growth 5Y18.3%
Sales Q2Q%7.16%

3.2 Future

  • Based on estimates for the next years, ABMD will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.71% on average per year.
  • ABMD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.13% yearly.
EPS Next Y3.83%
EPS Next 2Y9.68%
EPS Next 3Y14%
EPS Next 5Y15.71%
Revenue Next Year10.29%
Revenue Next 2Y12.97%
Revenue Next 3Y13.62%
Revenue Next 5Y11.13%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ABMD Yearly Revenue VS EstimatesABMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B
ABMD Yearly EPS VS EstimatesABMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2 4 6 8

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 78.72, which means the current valuation is very expensive for ABMD.
  • ABMD's Price/Earnings ratio is a bit cheaper when compared to the industry. ABMD is cheaper than 71.69% of the companies in the same industry.
  • ABMD's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.41.
  • A Price/Forward Earnings ratio of 66.96 indicates a quite expensive valuation of ABMD.
  • 73.06% of the companies in the same industry are more expensive than ABMD, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 25.64. ABMD is valued rather expensively when compared to this.
Industry RankSector Rank
PE 78.72
Fwd PE 66.96
ABMD Price Earnings VS Forward Price EarningsABMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 69.41% of the companies in the same industry are more expensive than ABMD, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, ABMD is valued cheaply inside the industry as 80.82% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 79.09
EV/EBITDA 55.82
ABMD Per share dataABMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ABMD does not grow enough to justify the current Price/Earnings ratio.
  • The decent profitability rating of ABMD may justify a higher PE ratio.
  • ABMD's earnings are expected to grow with 14.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)20.54
PEG (5Y)2.55
EPS Next 2Y9.68%
EPS Next 3Y14%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for ABMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABIOMED INC

NASDAQ:ABMD (12/21/2022, 8:15:55 PM)

After market: 381.3 +0.28 (+0.07%)

381.02

+0.23 (+0.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-01
Earnings (Next)02-01
Inst Owners0%
Inst Owner Change0%
Ins Owners1.66%
Ins Owner Change0%
Market Cap17.18B
Revenue(TTM)1.07B
Net Income(TTM)266.76M
Analysts70
Price Target375.36 (-1.49%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.37%
Min EPS beat(2)-5.24%
Max EPS beat(2)15.98%
EPS beat(4)3
Avg EPS beat(4)8.26%
Min EPS beat(4)-5.24%
Max EPS beat(4)15.98%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-14.37%
Min Revenue beat(2)-16.89%
Max Revenue beat(2)-11.85%
Revenue beat(4)0
Avg Revenue beat(4)-11.39%
Min Revenue beat(4)-16.89%
Max Revenue beat(4)-6.39%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)19.09%
PT rev (3m)N/A
EPS NQ rev (1m)4.13%
EPS NQ rev (3m)N/A
EPS NY rev (1m)1.46%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)-3.26%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.36%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 78.72
Fwd PE 66.96
P/S 16
P/FCF 79.09
P/OCF 68.45
P/B 11.16
P/tB 12.15
EV/EBITDA 55.82
EPS(TTM)4.84
EY1.27%
EPS(NY)5.69
Fwd EY1.49%
FCF(TTM)4.82
FCFY1.26%
OCF(TTM)5.57
OCFY1.46%
SpS23.82
BVpS34.15
TBVpS31.36
PEG (NY)20.54
PEG (5Y)2.55
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 15.72%
ROE 17.32%
ROCE N/A
ROIC 12.19%
ROICexc 25.66%
ROICexgc 30.76%
OM 23.66%
PM (TTM) 24.84%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)29.16%
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-10.63%
ROICexgc growth 5Y-2.2%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-5.22%
OM growth 5Y4.22%
PM growth 3Y-26.75%
PM growth 5Y2.49%
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 122.5%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 81.43%
Current Ratio 7.93
Quick Ratio 7.17
Altman-Z 68.47
F-Score6
WACC9.07%
ROIC/WACC1.34
Cap/Depr(3y)188.19%
Cap/Depr(5y)276.96%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)138.14%
Profit Quality(5y)123.31%
High Growth Momentum
Growth
EPS 1Y (TTM)-3.78%
EPS 3Y-2.48%
EPS 5Y30.92%
EPS Q2Q%26.21%
EPS Next Y3.83%
EPS Next 2Y9.68%
EPS Next 3Y14%
EPS Next 5Y15.71%
Revenue 1Y (TTM)10.32%
Revenue growth 3Y10.27%
Revenue growth 5Y18.3%
Sales Q2Q%7.16%
Revenue Next Year10.29%
Revenue Next 2Y12.97%
Revenue Next 3Y13.62%
Revenue Next 5Y11.13%
EBIT growth 1Y-2.58%
EBIT growth 3Y4.52%
EBIT growth 5Y23.29%
EBIT Next Year13.8%
EBIT Next 3Y20.3%
EBIT Next 5Y16.96%
FCF growth 1Y-11.7%
FCF growth 3Y6.24%
FCF growth 5Y31%
OCF growth 1Y-11.94%
OCF growth 3Y4.21%
OCF growth 5Y19.91%

ABIOMED INC / ABMD FAQ

What is the fundamental rating for ABMD stock?

ChartMill assigns a fundamental rating of 6 / 10 to ABMD.


What is the valuation status of ABIOMED INC (ABMD) stock?

ChartMill assigns a valuation rating of 0 / 10 to ABIOMED INC (ABMD). This can be considered as Overvalued.


Can you provide the profitability details for ABIOMED INC?

ABIOMED INC (ABMD) has a profitability rating of 6 / 10.


What are the PE and PB ratios of ABIOMED INC (ABMD) stock?

The Price/Earnings (PE) ratio for ABIOMED INC (ABMD) is 78.72 and the Price/Book (PB) ratio is 11.16.


How financially healthy is ABIOMED INC?

The financial health rating of ABIOMED INC (ABMD) is 9 / 10.